Benitec Biopharma Inc.
Company & revenue
About Benitec Biopharma Inc.
Who they are
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia.
Detailed revenue, brand and relationship research has not yet been completed for BNTC.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
35
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
55
Fair
Financial Strength
61
Business Quality / Moat
40
Management
60
Growth Quality
100
Risk / Durability
0
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Model Outlook
12-month model · What does the model think happens next?
Outperformance analysis is not currently available.
WSS View
The quick read
WSS currently sees meaningful weaknesses in the company-strength profile.
A current Opportunity Score is not available.
The 12-month model outlook is not currently available.
- •Asset quality scores strongly
- •M&A headline · Aug 26, 2026
- •Valuation is a weaker part of the current profile
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for BNTC
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can BNTC fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is BNTC likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for BNTC to reach sustainable profitability?
- •What future growth or profitability would be needed to justify BNTC's current valuation?
- •What does the current fundamental change risk warning mean for the reliability or interpretation of BNTC's score?
Essential Investment Snapshot
Wall Street Score
35
Market Cap
$308.5M
P/E Ratio
-10.2
EPS
$-0.98
52-Week High
$16.76
52-Week Low
$9.26
Beta
0.27
Analyst Target
$21.00
Shares Outstanding
46.6M
Total Revenue
$0
Total Debt
$762K
Dividend
No current dividend
Liquidation Value / Share
$3.80
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for BNTC
Detected from reported data — verify before acting.M&A headline · Aug 26, 2026
AWM Investment Company Inc. Acquires New Position in Benitec Biopharma Limited $BNTC — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
Defense WorldCommunity Sentiment
0 active · 0 total callsNo personal call yet on BNTC.
What the Bulls Say
- +Product opportunity: Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene thera.
What the Bears Say
- −Diluted weighted-average shares increased 28.6% year over year.
- −Negative free cash flow may increase the need for outside financing and dilution.
Bull and bear cases summarize disclosed catalysts, growth opportunities and risks; they are not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
7 historical score records availablePrevious Score
35
Sep 29, 2026
Change
Unchanged
Current Score
35
Oct 1, 2026
Category Changes
BNTC score was unchanged.
Projected Score
Projected Score
29
Projected Change
-6.7%
Preliminary comparable-period financial changes suggest decline of approximately 6.7 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$8.98
Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Related Companies
BiotechnologyNews
Benitec Biopharma (NASDAQ:BNTC) Stock Crosses Below 50 Day Moving Average – Here’s Why
After Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC)
Benitec Biopharma (BNTC) Projected to Release Quarterly Earnings on Monday
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial